Bimatoprost, Prostamide Activity, and Conventional Drainage | Zendy

Zhou Wan | Zendy; David F. Woodward | Zendy; Clive L. Cornell | Zendy; Hans Fliri | Zendy; Jose L. Martos | Zendy; Simon N. Pettit | Zendy; Jenny W. Wang | Zendy; Alexander B. Kharlamb | Zendy; Larry A. Wheeler | Zendy; Michael E. Garst | Zendy; K Landsverk | Zendy; Craig S. Struble | Zendy; W. Daniel Stamer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bimatoprost, Prostamide Activity, and Conventional Drainage

Author(s) -

Zhou Wan,

David F. Woodward,

Clive L. Cornell,

Hans Fliri,

Jose L. Martos,

Simon N. Pettit,

Jenny W. Wang,

Alexander B. Kharlamb,

Larry A. Wheeler,

Michael E. Garst,

K Landsverk,

Craig S. Struble,

W. Daniel Stamer

Publication year - 2007

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.07-0080

Subject(s) - bimatoprost , in vivo , intraocular pressure , trabecular meshwork , medicine , ophthalmology , in vitro , prostaglandin , antagonist , pharmacology , chemistry , endocrinology , ocular hypertension , receptor , biology , biochemistry , microbiology and biotechnology

Despite structural similarity with prostaglandin F(2 alpha), the ocular hypotensive agent bimatoprost (Lumigan; Allergan, Inc., Irvine, CA) shows unique pharmacology in vitro and functional activity in vivo. Unfortunately, the precise mechanisms that underlie bimatoprost's distinctive impact on aqueous humor dynamics are unclear. The purpose of the present study was to investigate the effects of bimatoprost and a novel prostamide-selective antagonist AGN 211334 on human conventional drainage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research